Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati's adagrasib as Krazati for a form of lung cancer. Krazati has been cleared as a treatment for ...

BMS claimed rights to Krazati when it acquired Mirati Therapeutics last year in a $5.8 billion deal. So far, neither of the KRAS drugs have lived up to their initial sales expectations ...

Pelareorep combined with modified FOLFIRINOX, with or without Tecentriq, shows an acceptable safety profile in metastatic PDAC patients. All patients experienced side effects, with some severe cases, ...